Investigating the combinatory effect of Sclerocarya birrea with doxorubicin against selected colorectal cancer cell lines

Thembelihle Nxasana; Innocensia Mangoato; Patriciah Masiu; Abhay Mishra; Motlalepula Matsabisa

doi:10.33393/dti.2024.3219

Authors

Thembelihle Nxasana Department of Pharmacology, University of the Free State , Faculty of Health Sciences, School of Medicine, Bloemfontein - South Africa https://orcid.org/0000-0001-7114-9302
Innocensia Mangoato Department of Pharmacology, University of the Free State , Faculty of Health Sciences, School of Medicine, Bloemfontein - South Africa https://orcid.org/0000-0003-1192-1887
Patriciah Masiu Department of Pharmacology, University of the Free State , Faculty of Health Sciences, School of Medicine, Bloemfontein - South Africa https://orcid.org/0000-0002-8148-7548
Abhay Mishra Department of Pharmacology, University of the Free State, Faculty of Health Sciences, School of Medicine, Bloemfontein - South Africa and Cosmetics and Natural Products Research Center (CosNat), Faculty of Pharmaceutical Sciences, Naresuan University , Phitsanulok - Thailand https://orcid.org/0000-0002-2224-0852
Motlalepula Matsabisa Department of Pharmacology,University of the Free State , Faculty of Health Sciences, School of Medicine, Bloemfontein - South Africa https://orcid.org/0000-0003-2921-8882

DOI:

https://doi.org/10.33393/dti.2024.3219

Keywords:

Colorectal cancer, Doxorubicin drug resistance, Sclerocarya birrea, Synergy, Verapamil

Abstract

Introduction: Colorectal cancer incidences continue to increase annually, worldwide. Herbal plants with antiproliferative properties received research interest as agents that can be adjuvant therapies with chemotherapy drugs to enhance their efficacy and reverse drug resistance.

Methods: Sclerocarya birrea ethanolic (SBE) and aqueous (SBW) extracts combined with doxorubicin (DOX) against drug-sensitive and drug-resistant colorectal cancer cells were investigated for their potential adjuvant and drug resistance reversal. The extracts were assessed for their potential anticancer activities on HCT15 and HT29 cell lines as well as their doxorubicin potentiating and drug resistance reversal effects respectively. The extracts were assessed for their cytotoxicity on normal 3T3-L1 fibroblast cells.

Results: Both SBE and SBW extracts exhibited no toxicity against normal 3T3 cells and showed low activity on the HT29 cell line. Contrarily, resistant HCT15 cells showed moderate to low activity with significantly higher inhibitory concentration (IC)₅₀ values. The combination of SBE with DOX and SBW with DOX resulted in antagonistic interactions, causing an increase in IC₅₀ values for HT29 and HCT15 cells. In contrast, the combination of DOX and verapamil (VER) produced an additive effect, with no change in their IC₅₀ values.

Conclusion: Based on the findings from the combination treatment, the SBE and SBW extracts demonstrated higher efficacy and synergistic effects combined with DOX at IC₇₅ compared to the combination of DOX and VER, suggesting their potential as anticancer agents. However, further research on both the SBE and SBW extracts’ mechanisms of action and in vivo effects is warranted.

Downloads

Download data is not yet available.

References

Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers (Basel). 2021;13(9):2025. https://doi.org/10.3390/cancers13092025 PMID:33922197

McCabe M, Perner Y, Magobo R, Mirza S, Penny C. Descriptive epidemiological study of South African colorectal cancer patients at a Johannesburg Hospital Academic institution. JGH Open. 2019;4(3):360-367. https://doi.org/10.1002/jgh3.12248 PMID:32514437

Yun UJ, Lee JH, Shim J, et al. Anti-cancer effect of doxorubicin is mediated by downregulation of HMG-Co A reductase via inhibition of EGFR/Src pathway. Lab Invest. 2019;99(8):1157-1172. https://doi.org/10.1038/s41374-019-0193-1 PMID:30700846

Pilotto Heming C, Muriithi W, Wanjiku Macharia L, Niemeyer Filho P, Moura-Neto V, Aran V. P-glycoprotein and cancer: what do we currently know? Heliyon. 2022;8(10):e11171. https://doi.org/10.1016/j.heliyon.2022.e11171 PMID:36325145

Zhang T, Ma K, Huang J, et al. CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma. Oncotarget. 2017;8(66):110052-110063. https://doi.org/10.18632/oncotarget.22123 PMID:29299129

Aiello P, Sharghi M, Mansourkhani SM, et al. Medicinal plants in the prevention and treatment of colon cancer. Oxid Med Cell Longev. 2019;2019:2075614. https://doi.org/10.1155/2019/2075614 PMID:32377288

Esmeeta A, Adhikary S, Dharshnaa V, et al. Plant-derived bioactive compounds in colon cancer treatment: an updated review. Biomed Pharmacother. 2022;153:113384. https://doi.org/10.1016/j.biopha.2022.113384 PMID:35820317

Huang XM, Yang ZJ, Xie Q, Zhang ZK, Zhang H, Ma JY. Natural products for treating colorectal cancer: a mechanistic review. Biomed Pharmacother. 2019;117:109142. https://doi.org/10.1016/j.biopha.2019.109142 PMID:31238258

Yang C, Mai Z, Liu C, Yin S, Cai Y, Xia C. Natural products in preventing tumor drug resistance and related signaling pathways. Molecules. 2022;27(11):3513. https://doi.org/10.3390/molecules27113513 PMID:35684449

Kamanula M, Munthali CY, Kamanula JF. Nutritional and phytochemical variation of Marula (Sclerocarya birrea) (Subspecies caffra and birrea) fruit among nine international provenances tested in Malawi. Int J Food Sci. 2022;2022:4686368. https://doi.org/10.1155/2022/4686368 PMID:36268477

Cádiz-Gurrea ML, Lozano-Sánchez J, Fernández-Ochoa Á, Segura-Carretero A. Enhancing the yield of bioactive compounds from Sclerocarya birrea bark by green extraction approaches. Molecules. 2019;24(5):966. https://doi.org/10.3390/molecules24050966 PMID:30857290

Masoko P, Mmushi TJ, Mogashoa MM, Mokgotho MP, Mampuru LJ, Howard RL. In vitro evaluation of the antifungal activity of Sclerocarya birrea extracts against pathogenic yeasts. Afr J Biotechnol. 2008;7(20):3521-3526.

Daniel JA, Mathiyazhagan J, Anbazhagan M, Jayaraj R, Gothandam KM. Phytochemistry and pharmacology of Sclerocarya birrea (A. Rich.) Hochst.: a review. In: Pullaiah T, ed. Bioactives and pharmacology of medicinal plants. Apple Academic Press; 2022:139-147. https://doi.org/10.1201/9781003281658-10.

Mohammed M, Adamu H, Magashi L, Sarkinnoma A, Daniel S, Zakiyya R, Aisha S. Purification and characterization of extracts from the stem bark of Sclerocarya birrea (Marula). International Journal of Modelling and Applied Science Research. 2023;28(9):141-152. Online https://www.cambridgenigeriapub.com/wp-content/uploads/2023/07/CJMASR.VOL_.28.NO_.9-9.pdf (Accessed July 2024)

Nyoni S, Muzenda E, Mukaratirwa-Muchanyereyi N. Characterization and evaluation of antibacterial activity of silver nanoparticles prepared from Sclerocarva birrea stem bark and leaf extracts. Nano Biomed Eng. 2019;11(1):28-34. https://doi.org/10.5101/nbe.v11i1.p28-34

Abdulhamid A, Sani I, Fakai IM, Kankiya IH, Shinkafi TS. Antibacterial potentials of compounds isolated from the stem bark extract of Sclerocarya birrea (A. Rich, Hochst). J Appl Sci. 2019;19(3):210-216. https://doi.org/10.3923/jas.2019.210.216

Indrayanto G, Putra GS, Suhud F. Validation of in-vitro bioassay methods: application in herbal drug research. In: Al-Majed AA. Profiles of drug substances, excipients and related methodology. Vol 46. Academic Press; 2021:273-307. https://doi.org/10.1016/bs.podrm.2020.07.005

Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440-6. doi: 10.1158/0008-5472.CAN-09-1947. PMID: 20068163.

Aftab A, Yousaf Z, Rashid M, et al. Vegetative part of Nigella sativa L. potential antineoplastic sources against Hep2 and MCF7 human cancer cell lines. J Taibah Univ Sci. 2023;17(1):2161294. https://doi.org/10.1080/16583655.2022.2161294

Lin SR, Chang CH, Hsu CF, et al. Natural compounds as potential adjuvants to cancer therapy: preclinical evidence. Br J Pharmacol. 2020;177(6):1409-1423. https://doi.org/10.1111/bph.14816 PMID:31368509

Tanih NF, Ndip RN. The acetone extract of Sclerocarya birrea (Anacardiaceae) possesses antiproliferative and apoptotic potential against human breast cancer cell lines (MCF-7). Sci World J. 2013;2013(1):956206. https://doi.org/10.1155/2013/956206 PMID:23576913

Al-Rajhi AMH, Yahya R, Abdelghany TM, et al. Anticancer, anticoagulant, antioxidant and antimicrobial activities of Thevetia peruviana Latex with molecular docking of antimicrobial and anticancer activities. Molecules. 2022;27(10):3165. https://doi.org/10.3390/molecules27103165 PMID:35630642

Luo M, Zhou L, Huang Z, et al. Antioxidant therapy in cancer: rationale and progress. Antioxidants. 2022;11(6):1128. https://doi.org/10.3390/antiox11061128 PMID:35740025

Piskounova E, Agathocleous M, Murphy MM, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015;527(7577):186-191. https://doi.org/10.1038/nature15726 PMID:26466563

Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037-1043. https://doi.org/10.1007/s11064-005-6978-1 PMID:16258853

Eid SY, Althubiti MA, Abdallah ME, Wink M, El-Readi MZ. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes. Phytomedicine. 2020;77:153280. https://doi.org/10.1016/j.phymed.2020.153280 PMID:32712543

Poofery J, Khaw-On P, Subhawa S, et al. Potential of Thai herbal extracts on lung cancer treatment by inducing apoptosis and synergizing chemotherapy. Molecules. 2020;25(1):231. https://doi.org/10.3390/molecules25010231 PMID:31935933